| REDD14NP - Recruiting |
 |
 |
 Share
REDD14NP– QuarkThis Phase I study is recruiting patients with wet macular degeneration to receive a single injection of a drug designed to interfere with a gene that seems to be active in creating AMD. This is a safety trial and 42 patients in multiple centers in the U.S. and Israel will participate. For more information: click here Another Phase I study is also recruiting and will use different doses of the drug with 27 patients in the U.S. For more information: click here |
Search
Get News!
SIGN UP NOW
To receive the "AMD Update" and keep up-to-date with the latest research & treatment options:
For Email Newsletters you can trust